Show simple item record

dc.contributor.authorSolmaz, Şerife
dc.contributor.authorAcar, Celal
dc.contributor.authorSeyhanlı, Ahmet
dc.contributor.authorSevindik, Ömür Gökmen
dc.contributor.authorPişkin, Özden
dc.contributor.authorÖzcan, Mehmet Ali
dc.contributor.authorDemirkan, Fatih
dc.contributor.authorÜndar, Bülent
dc.contributor.authorAlacacıoğlu, İnci
dc.contributor.authorÖzsan, Güner Hayri
dc.date.accessioned2021-05-03T10:59:24Z
dc.date.available2021-05-03T10:59:24Z
dc.date.issued2020en_US
dc.identifier.citationSolmaz, Ş., Acar, C., Seyhanlı, A., Sevindik, Ö. G., Pişkin, Ö., Özcan, M. A. ... Özsan, G. H. (2020). What are the factors affecting survival after autologous stem cell transplantation in patients with multiple myeloma? Indian Journal of Transplantation, 14(1), 57-62. https://dx.doi.org/10.4103/ijot.ijot_15_19en_US
dc.identifier.issn2212-0017
dc.identifier.issn2212-0025
dc.identifier.urihttps://dx.doi.org/10.4103/ijot.ijot_15_19
dc.identifier.urihttps://hdl.handle.net/20.500.12511/6806
dc.description.abstractIntroduction: High-dose chemotherapy (HDC) and autologous stem cell transplantation(ASCT) still remains in the treatment of myeloma patients even during the period of new agents. Materials and Methods: We analysed the prognostic affect of pretransplant characteristics and transplant modalities on response, in 150 autologous transplant of 144 multiple myeloma (MM) patients who were transplanted in our centre between 2008 to 2017. We evaluated the affect of age, type of MM, previous treatment regimens, status pre and postfrom transplantation, time of ASCT, neutrophil and platelet engraftmant days, dose of reinfused CD34+ cells, plasma cell infiltration, international staging system(ISS) and Durie -Salmon stage at diagnosis. We examined the affect of these status on overall survival(OS) and eventfree survival(EFS). Results: The median OS and EFS after transplanation were 41 and 28 months, respectively. Median OS after the diagnosis was 57 months. Transplant-related mortality was 3,3%. We found that the lower beta 2- microglobulin levels,lower ISS stage,lower plasma cell infiltration, achievement good responds at the +100th day of post transplant were statistically significant independent predictor factors for longer EFS and OS. When the patients were given chemotherapy regimen with bortezomib before transplantation, these patients were seen to be a better response rate. There was showed a relationship between the using of bortezomib before transplantation with EFS(P = 0.017), but there was no relationship with OS. Conclusions: Our analysis confirms HDCT-ASCT as an effective and safe therapeutic strategy in multiple myeloma patients. This results were independent of age, first line treatment regimens and renal insufficiency. Patients with a high ISS stage were found to have shorter survival(P = 0.002). However, the EFS and OS were longer of the patients whose have good response at the 100th day of transplantation(P = 0,002, P = 0,02).en_US
dc.language.isoengen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectAutologous Stem Cell Transplantationen_US
dc.subjectEvent-Free Survivalen_US
dc.subjectMultiple Myelomaen_US
dc.subjectOverall Survivalen_US
dc.titleWhat are the factors affecting survival after autologous stem cell transplantation in patients with multiple myeloma?en_US
dc.typearticleen_US
dc.relation.journalIndian Journal of Transplantationen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.authorid0000-0001-9636-4113en_US
dc.identifier.volume14en_US
dc.identifier.issue1en_US
dc.identifier.startpage57en_US
dc.identifier.endpage62en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.4103/ijot.ijot_15_19en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess